Get the Stockscreener App
0.2878
4.80%
-0.0145
After Hours:
.28
-0.0078
-2.71%
Cue Biopharma Inc stock is traded at $0.2878, with a volume of 234.93K.
It is down -4.80% in the last 24 hours and down -8.95% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.3023
Open:
$0.3041
24h Volume:
234.93K
Relative Volume:
0.21
Market Cap:
$26.26M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.3163
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
-0.03%
1M Performance:
-8.95%
6M Performance:
-63.10%
1Y Performance:
-74.30%
1-Day Range:
$0.2831
$0.3059
1-Week Range:
$0.271
$0.31
52-Week Range:
$0.2302
$1.13
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.2878 | 27.58M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
CUE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Update Recap: Can Cue Biopharma Inc disrupt its industryPortfolio Update Report & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Momentum Shift: Whats the MACD signal for OSR Holdings Inc Equity WarrantBull Run & Long-Term Safe Investment Ideas - baoquankhu1.vn
Stock Market Recap: Will Cue Biopharma Inc benefit from geopolitical trendsJuly 2025 Outlook & AI Powered Market Trend Analysis - baoquankhu1.vn
CUE Should I Buy - Intellectia AI
Cue Biopharma Sets 2026 Annual Meeting, Proposal Deadlines - TipRanks
Cue Biopharma sets April 13, 2026 annual meeting; February 28 deadline for shareholder proposals - TradingView
Cue’s CUE-401 well tolerated in mouse and NHP studies - BioWorld MedTech
Aug Technicals: Can Cue Biopharma Inc outperform in the next rallyJuly 2025 Levels & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Analyzing Cue Biopharma (NASDAQ:CUE) & Aardvark Therapeutics (NASDAQ:AARD) - Defense World
Autoimmune drug candidate CUE-401 passes early safety tests in animals - Stock Titan
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases - Bitget
Can Cue Biopharma Inc. outperform in the next rally2025 Earnings Surprises & Growth Focused Entry Point Reports - mfd.ru
Cue Biopharma Names Lucinda Warren Chief Financial Officer - The Globe and Mail
How Cue Biopharma Inc. stock performs in rising dollar environmentWeekly Gains Report & Daily Risk Controlled Trade Plans - mfd.ru
Cue Biopharma appoints industry veteran Lucinda Warren as chief financial and business officer - marketscreener.com
Cue Biopharma (CUE) Appoints New Chief Financial and Business Of - GuruFocus
Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Financial Officer, Effective February 9, 2026 - marketscreener.com
Cue Biopharma Names Lucinda Warren Chief Financial And Business Officer - Nasdaq
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer - Bitget
Cue Biopharma Appoints Lucinda Warren as Chief Financial and Business Officer - TradingView
Is Cue Biopharma Inc. stock attractive after correctionTreasury Yields & Short-Term High Return Ideas - mfd.ru
How Cue Biopharma Inc. stock reacts to job market dataInflation Watch & Proven Capital Preservation Tips - mfd.ru
Can Cue Biopharma Inc outperform in the next rallyJuly 2025 Chart Watch & Daily Stock Momentum Reports - baoquankhu1.vn
What’s the RSI of Cue Biopharma Inc. stockQuarterly Growth Report & Reliable Breakout Forecasts - mfd.ru
Is Cue Biopharma Inc. stock forming a triangle pattern2025 Market WrapUp & AI Driven Stock Movement Reports - mfd.ru
Volatility Watch: Is Cue Biopharma Inc forming a bullish divergence2025 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
CUE Stock Price, Forecast & Analysis | CUE BIOPHARMA INC (NASDAQ:CUE) - Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Biotech Stocks Surge After Hours: IO Biotech Jumps 19%, Cue Biopharma And Cabaletta Bio Follow - Nasdaq
Options Flow: Can Cue Biopharma Inc disrupt its industryMarket Risk Analysis & Risk Managed Investment Strategies - baoquankhu1.vn
Is Cue Biopharma Inc. (1UC) stock overpriced at current multiples2025 Trading Volume Trends & Growth Oriented Trading Recommendations - bollywoodhelpline.com
Is Cue Biopharma Inc benefiting from interest rate changesInsider Buying & Daily Stock Momentum Reports - baoquankhu1.vn
Cue Biopharma (NASDAQ:CUE) Shares Up 9% – Should You Buy? - Defense World
Activity Recap: Whats the profit margin of Cue Biopharma IncJuly 2025 Short Interest & Low Drawdown Momentum Ideas - baoquankhu1.vn
Analyst Upgrade: Can Cue Biopharma Inc be recession proofJuly 2025 Snapshot & Daily Growth Stock Investment Tips - baoquankhu1.vn
Cue Biopharma launches proposed public offering of shares and warrants - MSN
Can Cue Biopharma Inc. stock outperform in 2025 bull marketWeekly Investment Recap & AI Driven Price Forecasts - Улправда
How sustainable is Cue Biopharma Inc. stock dividend payout2025 Growth vs Value & Short-Term Trading Alerts - Улправда
Why Cue Biopharma Inc. stock is trending among retail tradersStock Surge & Verified Momentum Stock Ideas - Улправда
What sentiment indicators say about Cue Biopharma Inc. stock2025 Pullback Review & Reliable Momentum Entry Alerts - Улправда
Aug Big Picture: Why Cue Biopharma Inc. stock remains resilient2025 Top Gainers & Consistent Return Strategy Ideas - Улправда
Why Cue Biopharma Inc. stock remains resilientJuly 2025 Highlights & Free Safe Capital Growth Stock Tips - Улправда
Will Cue Biopharma Inc. stock see insider buyingStop Loss Placement Tips & Small Entry Cost Investments - Улправда
Institution Moves: Will Cue Biopharma Inc 1UC stock benefit from mergersTrade Risk Assessment & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Is Cue Biopharma Inc. stock attractive for growth ETFs2026 world cup usa national team semifinals top scorers high defensive line tactical prediction expert opinion - Улправда
2026 world cup lineups insights: Will Cue Biopharma Inc. stock benefit from AI adoption2026 world cup usa national team round of 32 young talents transition play tactical prediction insights - ulpravda.ru
EBIT per share of Cue Biopharma, Inc. – SWB:1UC - TradingView — Track All Markets
CUE Insider Trading - Quiver Quantitative
Is Cue Biopharma Inc a good long term investmentStock Screening Results & Big Gains Low Budget - earlytimes.in
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):